Introduction
Amyloid peptide (A) deposition in the extracellular region is one of the pathological hallmarks of Alzheimer's disease (AD). A is derived from sequential cleavage of the amyloid precursor protein (APP), ectodomain shedding by -secretase, and intramembrane cleavage by -secretase (Haass, 2004; Querfurth & LaFerla 2010; Selkoe & Schenk, 2003) . As ectodomain shedding of APP by -secretase occurs within the A domain, it has the potential to preclude generation of the A peptide. In addition, a secreted fragment of APP generated by -cleavage (sAPP) was shown to have neurotrophic and neuroprotective properties (Furukawa et al., 1996; Stein et al., 2004 ).
An enhancement in -secretase activity is considered to be a therapeutic approach for AD (Fahrenholz, 2007; Lichtenthaler, 2011) . Several members of the ADAM (a disintegrin and metalloprotease) family, such as ADAM9, ADAM10, and ADAM17, have been reported to exhibit -secretase activity (Kim et al., 2008) . However, two recent studies, one using gene knockdown in primary neurons and the other using neurons derived from ADAM10 conditional knockout mice, demonstrated that the main -secretase appears to be ADAM10 (Jorissen et al., 2010; Kuhn et al., 2010) .
Furthermore, ADAM10 overexpression in the AD mouse model reduced A deposition, which indicated that activation of -secretase is beneficial for the prevention of AD (Postina et al., 2004) . Nardilysin (EC 3.4.24.61 , N-arginine dibasic convertase; NRDc) was initially identified as a metalloendopeptidase of the M16 family Pierotti et al., 1994) . We rediscovered NRDc as a specific binding partner of HB-EGF (Nishi et al., 2001) , and demonstrated that NRDc enhances ectodomain shedding of HB-EGF through activation of ADAM17 (Nishi et al., 2006) . Our subsequent studies showed that ectodomain shedding of multiple membrane proteins such as TNF- and APP is also enhanced by NRDc (Hiraoka et al., 2007; Hiraoka et al., 2008) . Regarding APP, NRDc enhanced ADAM9-, ADAM10-, and ADAM17-induced -cleavage, which resulted in the decreased generation of A in vitro (Hiraoka et al., 2007) .
We demonstrated using NRDc-deficient mice (Nrd1 -/-) that NRDc regulates myelination through the modulation of neuregulin1 (NRG1) shedding. Similar to APP, the membrane precursor of NRG1 is shown to be cleaved by ADAMs (-secretase) and BACE1 (-secretase) at two adjacent sites (Luo et al. 2011; Willem et al., 2006) . We showed that ectodomain shedding of NRG1 is impaired in Nrd1 -/-fibroblasts and brains.
Moreover, gain of function experiments in cells revealed that NRDc enhances ADAM17-and BACE1-mediated NRG1 shedding (Ohno et al., 2009 ). These findings suggested that NRDc is able to modulate both -and -secretase activity.
Here, to clarify the pathophysiological role of NRDc in AD, we evaluated the in vivo effect of NRDc overexpression or deletion on -and -secretase activity. We found that NRDc controls A formation by mainly regulating -secretase in vivo.
Methods

Animals
The background of mice used for all experiments was C57/BL6. Transgenic mice expressing mouse NRDc under the control of a forebrain neuron-specific CamkII promoter and NRDc-deficient mice (Acc.No. CDB0466K:
http://www.cdb.riken.jp/arg/mutant%20mice%20list.html) were described previously (Ohno et al., 2009 for all experiments with the exception of A42 ELISA, in which a similar number of male and female mice were analyzed.
Immunohistochemical staining, image capture and quantitative analysis
Immunohistochemical staining of mouse brain sections was performed as described previously (Ohno et al., 2009 ). Anti-GFAP (Z0334; DakoCytomation, Denmark),
anti-F4/80 (BM8: BMA Biomedicals, Switzerland), anti-APP (A8717; Sigma, USA), anti-NRDc (#2371 raised in our laboratory) (Ohno et al., 2009) Supplementary Fig. 1A , and E). Plaque number, plaque surface area and whole brain surface area were measured by the dedicated software (Dynamic Cell Count 
Western blot analysis
The preparation of total cell extracts and Western blot analysis were performed as described previously (Nishi et al., 2006) . Samples of conditioned media were prepared after concentration by Amicon Ultra Centrifugal Filter Units (Millipore). Samples of mouse brain extracts were prepared as described elsewhere (Kim et al., 2008) . The anti-APP antibody (A8717; Sigma) was used to recognize the full-length and C83 fragment of APP. Anti-sAPP and sAPP antibodies were described previously (Kuhn et al., 2010) . The anti-APP C-terminal antibody 2C11 was also described previously (Kuhn et al., 2012) . Anti-NRDc (mouse monoclonal #102 and rat monoclonal #1)
antibodies were raised in our laboratory. The anti- actin antibody (Santa Cruz) was used for the loading control.
RT-PCR
Total RNA extraction, cDNA synthesis, and quantitative real-time PCR were carried out as described previously (Ohno et al., 2009 
Measuring A by sandwich ELISA
A frozen hemisphere was homogenized in four brain volumes of Tris-buffered saline (TBS) containing protease inhibitor cocktail (Complete Mini, Roche Diagnostic) and 2mM of 1,10-phenanthroline and was centrifuged at 100,000g for one hour at 4C. The supernatant was saved as a TBS-soluble fraction. The pellet was resuspended in 6.25M
guanidine HCL in 50mM Tris, pH8.0 and nutated for two hours at RT, followed by a second centrifugation at 20,800g for 20 min at 4C. The supernatant was saved as a guanidine-extracted fraction (GuHCL-soluble). The concentration of A in the TBSor GuHCL-soluble fraction of brain extracts was measured by sandwich ELISA as described previously (Hiraoka et al., 2007) .
Measuring IL-6 by sandwich ELISA
Protein expression levels of mouse IL-6 in brain extracts were measured using the DuoSet ELISA Development kit (R&D Systems, Inc.) according to the manufacturer's protocol.
-Secretase activity assay
-Secretase activity in brain extracts was measured using the -Secretase activity kit (R&D systems) according to the manufacturer's protocol.
Cell culture and transfections
HEK293 cells expressing APP (HEK293-APP) were cultured in Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine serum and 200 g/ml G418 in a humidified atmosphere of 95% air, 5% CO2 at 37 C (Murayama et al., 2006) .
Transfections of plasmid DNA and siRNA were carried out using X-treme GENE (Roche Diagnostics) according to the manufacturer's protocol. The sequences for siRNA duplexes against mouse NRDc and human ADAM10 were described previously (Hiraoka et al., 2007) .
Statistical analysis
Data are represented as the mean +/-s.e.m. Statistical analysis (unpaired Student's two-tailed t test) was performed using the Statview software package (SAS institute).
Results
Enhanced NRDc expression reduces A deposition in the forebrain of the AD mouse model
We generated transgenic mice expressing mouse NRDc under the control of a forebrain neuron-specific CamkII promoter (NRDc-Tg) (Ohno et al., 2009) 1B and data not shown). We also examined the mRNA levels of major candidates of -and -secretase in the forebrain. No significant differences were observed in adam10, adam17, or bace1 mRNA levels between APP-Tg and APP/NRDc-Tg mice (data not shown).
Amyloid plaques were detected by immunohistochemistry using an antibody for A ( Fig APP-Tg, n=6: APP/NRDc-Tg) (Fig. 2D ). We also quantitatively analyzed the amount of A using an ELISA, specific for A42. The concentration of A42 in both soluble (TBS-soluble) and insoluble (GuHCL-soluble) fractions of forebrain extracts was significantly lower in APP/NRDc-Tg mice than that in APP/Tg mice (Fig. 2E, and F) .
These results clearly demonstrated that the enhanced expression of NRDc reduces A deposition in vivo.
NRDc regulates -secretase activity in vitro and in vivo
To assess the activity of -secretase, we used an antibody (4B4) that specifically recognizes the -cleavage site of APP (Fig. 3A) . This antibody detects the C-terminal ending of sAPP, and thus detects neither the full-length of APP nor shorter forms of sAPP, such as sAPP (Kuhn et al., 2010) . We first performed gene knockdown of ADAM10 in HEK293 cells stably overexpressing APP (HEK293-APP) (Murayama et al., 2006) to assess the role of ADAM10 as -secretase in these cells. As expected, secreted sAPP in the conditioned medium and the C-terminal remnant of APP (C83) were markedly reduced in ADAM10-knocked down cells (Fig. 3B) , which indicated that ADAM10 is the main -secretase in HEK293-APP cells. Gene knockdown of NRDc in HEK293-APP cells also showed a clear reduction in secreted sAPP in the conditioned medium and C-terminal remnant of APP (C83) (Fig.3C) . Competition between -and -secretase was not observed in both cases because sAPP levels were not increased either by NRDc knockdown or ADAM10 knock-down (Fig. 3B , and C), in agreement with a previous report (Colombo et al., 2012) . Furthermore, co-precipitation of NRDc and ADAM10 was detected in HEK293-APP cells (Fig. 3D ), which suggested that NRDc physically and functionally interacts with ADAM10 and regulates its -secretase activity.
To examine the in vivo effect of NRDc on -cleavage, forebrain extracts were analyzed by immunoblotting with the anti-sAPP antibody. As shown in Figures 4A and B, the amount of sAPP was clearly higher in APP/NRDc-Tg mice than that in APP-Tg mice, indicating that the overexpression of NRDc enhances -secretase activity in vivo.
To examine the competitive effect of enhanced -secretase activity on -secretase in APP/NRDc-Tg mice, sAPPand -secretase activity levels were evaluated in brain extracts by immunoblotting and a peptide cleavage assay, respectively. While there were no statistically significant differences between APP-Tg and APP/NRDc-Tg mice, both sAPPand -secretase activity levels showed clear tendencies to be lower in APP/NRDc-Tg mice compared with APP-Tg mice ( Fig. 4B and C) .
To further define the in vivo role of NRDc in the regulation of -and -secretase activity, we examined endogenous sAPP and sAPP protein levels in To assess whether NRDc altered the A production prior to plaque formation, we measured Ausing ELISA in 3-month-old mice. At this early phase, no significant differences were observed in either soluble or insoluble A between APP-Tg and APP/NRDc-Tg mice (Supplementary Fig. 2A ). The amount of Ain 3-month-old APP-Tg mice was approximately 1/10 and 1/1000 that of 1-year-old mice in the soluble and insoluble fractions, respectively. Consistent with these results, no significant alterations were detected in the amount of sAPP and sAPP between the two genotypes; however sAPP tended to be higher and sAPP tended to be lower in APP/NRDc-Tg mice ( Supplementary Fig. 2B , and C).
NRDc overexpression does not affect reactive gliosis in the AD mouse model
Although reactive gliosis adjacent to plaques is one of the pathological features of AD, the role of an inflammatory response in AD still remains controversial (Morgan et al., 2005; Wyss-Coray, 2006) . As the pro-inflammatory role of NRDc has been suggested (Hiraoka et al., 2008; Kanda et al., 2012) , we examined the effect of NRDc on inflammatory responses that occurred in the AD mouse model. First, we examined the mRNA expression levels of TNF- and IL-6, inflammatory cytokines, and those of GFAP and F4/80, markers of responsive astrocytes and microglia, at 3 months and 1 year of age (Fig. 5A and B) . No significant difference was observed in these mRNA levels at one year of age (TNF- mRNA expression was not detectable), whereas IL-6 mRNA levels only were significantly higher in APP/NRDc-Tg mice than in APP-Tg mice at 3 months of age (Fig. 5A, and B) . To confirm an increase in protein levels, we measured IL-6 levels in total brain extracts using ELISA. However, no significant differences were observed in IL-6 protein levels between APP-Tg and APP/NRDc-Tg mice both at 3 months and 1 year of age (Fig. 5C ). We then evaluated the extent of microgliosis and astrogliosis by immunohistochemistry using the anti F4/80 antibody and anti-glial fibrillary acidic protein (GFAP) antibody, respectively (Fig. 5D , and F).
No alteration was observed in the number of either F4/80-positive or GFAP-positive cells between APP-Tg and APP/NRDc-Tg mice at both 3 months and 1 year old of age (Fig. 5E , and G), indicating that NRDc overexpression does not affect reactive gliosis in the AD mouse model.
Discussion
Our findings provide the first in vivo evidence that a metalloendopeptidase NRDc prevents amyloid plaque formation in the AD mouse model. Forebrain neuron-specific NRDc overexpression increased the level of sAPP and reduced A deposition, indicating that NRDc precludes A deposition through the activation of -secretases.
NRDc overexpression in NRDc-Tg mice was only modest (2-to 3-fold higher than that in wild-type mice), suggesting the physiological role of NRDc in the regulation of -secretase. In contrast, the level of sAPP was clearly lower in Nrd1 -/-brains than in Nrd1 +/+ brains. These results suggest that -secretase activity is critically regulated by the expression level of NRDc in vivo.
We identified NRDc as a cell surface binding partner of HB-EGF (Nishi et al., 2001).
We subsequently demonstrated that NRDc enhanced ectodomain shedding of not only HB-EGF, but also of APP, TNF- and neuregulin-1 (NRG1) (Hiraoka et al., 2007; Hiraoka et al., 2008; Nishi et al., 2006; Ohno et al., 2009 ). In cell culture experiments, NRDc enhanced ADAM9-, ADAM10-, and ADAM17-induced -cleavage, which resulted in the decreased generation of A. We previously demonstrated the binding of ADAM17 and NRDc (Nishi et al., 2006) . Furthermore, the recombinant protein of NRDc enhances ADAM17-mediated -cleavage in a peptide cleavage assay (Hiraoka et al., 2007) , while NRDc itself, which has endopeptidase activity, does not cleave A at the -cleavage site (Hiraoka et al., 2007) . NRDc may activate ADAM10 in a similar manner because we demonstrate here the complex formation of NRDc and ADAM10.
The activation of -secretase is considered to be a therapeutic approach for AD (Fahrenholz, 2007; Lichtenthaler, 2011) . This hypothesis was supported by the finding that ADAM10 overexpression reduced A deposition in the AD mouse model (Postina et al., 2004) . We show here that NRDc, an activator of ADAMs, diminished amyloid plaque load in vivo, which further supports this hypothesis.
We recently reported that NRDc regulates myelination in the central and peripheral nervous system by regulating NRG1 shedding. NRG1 shares a unique characteristic with APP in which both are cleaved by ADAMs and BACE1 at two different sites in the juxtamembrane region (Luo et al.; Willem et al., 2006) . We demonstrated that the overexpression of NRDc enhances ADAM17-and BACE1-mediated NRG1 shedding in a cell-based assay. Interestingly, NRDc has been shown to potentiate ADAM17-mediated NRG1 cleavage at the cell surface, whereas
NRDc enhanced BACE1 cleavage of NRG1 in intracellular compartments (Ohno et al., 2009 ). These findings are in line with a previous study, which showed that -secretase cleavage mainly occurs at the plasma membrane while -secretase cleavage mainly occurs in the endosome (Thinakaran & Koo, 2008) . In the present study, we examined the in vivo effect of NRDc on -secretase activity in the AD mouse model. Importantly, -secretase activity in the brain tended to be reduced rather than enhanced by the overexpression of NRDc, which is most probably due to the competitive effect of enhanced -secretase activity. -secretase activity was not affected by the deletion of 
Maes et al. analyzed gene expressions of blood mononuclear cells derived from
AD patients and found that NRDc is upregulated in AD patients compared to age-matched normal controls (Maes et al., 2007) . Our preliminary findings using autopsy samples also showed that NRDc expression in the cortical neurons of AD patients tends to be higher than that in control patients (data not shown). Given these results on human, we have to carefully interpret our findings in AD model mice. The increase of NRDc in AD patients could be a rescue response of the brain to the damage by A, which might not be sufficient to prevent the disease progression. On the other hand, we previously showed that NRDc is highly expressed in mouse brains at the early postnatal stage, but is expressed at a very low level in adult mice (Hiraoka et al., 2007; Ohno et al., 2009) . NRDc expression in the human brain may also be dynamically regulated in physiological and pathological processes. However, NRDc is highly expressed in the transgenic mouse model APP/NRDc-Tg throughout the life period from around postnatal day 5. The constantly high expression of NRDc may affect Apathology differently than it does in human AD. Future studies using a more sophisticated mouse model, such as an inducible tissue-specific knockout or overexpression of NRDc, will improve our understanding on the role of NRDc in AD.
We established a highly sensitive ELISA for NRDc (Kanda et al., 2012) , which enables us to measure NRDc in the serum or cerebrospinal fluid of AD patients. It is also important to further examine the expression levels of neuronal NRDc in AD autopsy samples. These data on human AD, together with mouse data, will clarify the pathophysiological roles of NRDc in AD. While a role of NRDc in human AD has not been sufficiently clarified, our finding that NRDc is a crucial in vivo regulator for -secretase activity may improve our understanding on the pathogenesis of AD.
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Figure legends
B and C. Immunostained brown color was automatically extracted by the dedicated software (Dynamic Cell Count System BZ-HIC) (B), followed by measurements of the plaque number and plaque surface area (C).
D. Whole brain surface area (D, H) was manually traced and measured by the software.
Aβ plaque load was defined as total plaque surface area / whole brain surface area. E, F, G, and H.
Higher magnification views of A, B, C, and D, respectively.
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